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PURIFICATION AND CHARACTERIZATION OF RIBONUCLEASE
FROM PSORIATIC SCALES*
MAURICE LISS, Pn.D. AND WALTER F. LEVER, M.D.
Psoriatic scales and psoriatic epidermis, in
comparison with callus and normal epidermis,
contain relatively large amounts of both RNA
and DNA (1—3). In addition, various hydrolytic
products of RNA have been detected in psoriatic
scales (2, 4). Santoianni and Rothman have
shown in biochemical studies that human epi-
dermis possesses RNase activity (5). Steigleder
and Raab, in histoehemical studies, have re-
cently reported that the RNase activity in the
horny layer of psoriatie lesions was stronger than
in the normal horny layer, and was present in
the entire stratum corneum (6).
In this paper, we wish to report on the isola-
tion and characterization of RNase from psori-
atic scales. The enzyme was found to be present
in high concentration and to have a very low
molecular weight.
MATERIALS AND METHODS
Preparation of ENA. Purified RNA was pre-
pared from bakers' yeast according to the pro-
cedure of Crestfield, Smith and Allen (7).
Phosphorus Analysis. Phosphorus was analyzed
according to a modification of the procedure of
Fiske and SubbaRow (8) in which the reducing
agent was a 1% solutiun of mono-methyl-p-amino-
phenol sulfate (Elon, Eastman Kodak Company)
in 3% NaHSO3.
Standard ENase Assay. RNase was assayed ac-
cording to the procedure of McDonald (9). One ml
of substrate solution containing 10 mg of RNA in
0.1 M sodium acetate buffer of pH 5.0 was incu-
bated for 15 minutes at 37° with a suitable aliquot
of enzyme solution. The final volume was adjusted
to 2 ml with 0.1 M sodium acetate buffer. The re-
action was stopped by the addition of 2 ml of
MacFadyen's reagent, consisting of 0.25%
uranium acetate in 2.5% trichloroacetic acid (10).
The suspension was left at room temperature for
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30 minutes and then centrifuged. The optical
density of five-fold aqueous dilutions of the
supernatant solution was determined in a
Beckman DU spectrophotometer at 260 mp and
280 mp using a ten-fold aqueous dilution of Mac-
Fadyen's regent as the blank solution. When the
extent of hydrolysis of RNA was determined also
by phosphorus analysis, 2 ml of the supernatant
solution were used. Enzyme, substrate and zero
time controls were done in the same way.
Protein Determination. Protein was determined
by the method of Lowry et. at (11) or of Warburg
and Christian (12).
Determination of the Nucteotide Composition of
RNA Before and After Prolonged Digestion with
Psoriatic RNase. Ten mg of purified yeast RNA
were incubated with 0.5 mg of purified psoriatic
RNase for 3 hours according to the standard pro-
cedure. The incubation mixture was then dialyzed
overnight at 4° against frequent changes of dis-
tilled water. The dialyzed material ("core" RNA)
was hydrolyzed with 0.15 ml of 70% HC1O4 for
one hour at 100°. The acid hydrolysate was diluted
with water and centrifuged. Aliquots were then
spotted on Whatman No. 1 filter paper (13). The
chromatogram was run for 36 hours using the iso-
propanol-HC1-water solvent system described by
Wyatt (14). The ultraviolet light absorbing purine
and pyrimidine compounds were eluted with 0.1N
HC1 for 2 hours at room temperature and examined
in a Beckman DU speetrophotometer. Adjacent
areas of equal size were treated in the same way
and served as blanks. The compounds were identi-
fied by their relative rates of chromatographic
migration and by spectral analysis. The com-
pounds were quantitated using the following
molecular extinction coefficients: adenine, 12.6 X
10 at 262.5 met; guanine, 11.1 X 10' at 249 mp;
cytosine, 10.0 X 10' at 276 met; and uracil, 8.15 X
10 at 260 mji (13). The base composition of puri-
fied yeast RNA before treatment with psoriatic
RNase was also determined by the HCI 04 hydroly-
sis procedure.
Starch Gel Elect rophoresis. For starch gel eleetro-
phoresis the discontinuous borate buffer system
described by Barret, Friesen and Astwood (15)
was used. Starch gel was prepared using hy-
drolyzed starch (Connaught Medical Research
Laboratories). The gel buffer contained 90 volumes
of 0.016 M Tris-0.0033 M citric acid and 10
volumes of 0.02 M lithium hydroxide—0.076 M
boric acid. The final pH was 8.0. The electrode
vessels contained a lithium borate buffer (0.1M
lithium hydroxideM.38 M boric acid) of pH 8.0.
Filter paper strips (either S & S No. 470 or What-
man No. 3), 6 x 10 mm, were moistened with the
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RNase solutions being studied and inserted into
the starch gel 22 cm from the cathode. The gel
was cooled to —5° during the electrophoresis and
a constant amperage of 60 mamp. was maintained.
The voltage was increased intermittently during
electrophoresis in order to maintain a 60 mamp.
current since resistance increased with the ad-
vance of borate ions. The electrophoresis was run
for approximately 3 hours, at which time the
borate "front" had advanced 24 cm from the
cathode. The protein bands resolved by electro-
phoresis were visualized by staining with water-
soluble nigrosin (15).
Preparation of DEAE-celtulose. DEAE-cellu-
lose (Brown Company), type 40, analytical grade,
was prepared in a batch process by treatment with
a 0.2 M NaOH solution containing 0.5 M NaC1
and followed by removal of excess alkali with dis-
tilled water. The ion exchange cellulose was then
stirred with a 1.5 M NaHCO3 solution, filtered, and
finally equilibrated by successive treatments
with a 0.05 M NaHCO3 solution.
EESULTS
RNase Activity in Psoriatic Scales. Acetone
powders of psoriatic scales were extracted with
0.25 N sulfuric acid according to the procedure
described under "Purification of Psoriatic
RNase". The acid extracts were neutralized with
a dilute NaOH solution and the sediment re-
moved by centrifugation. Determination of
ribonuclease activity in the neutralized acid
extracts revealed a release of acid uranyl acetate-
soluble nucleotides with a concomitant release of
almost equimolar amounts of organically bound
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Fra. 1. Ribonuclease activity of neutralized 0.25 N
sulfuric acid extracts of psoriatic scales. Assays
were performed according to the standard pro-
cedure. Solid circles represent organically bound
phosphorus. No inorganic phosphorus was re-
leased.
was liberated. The ribonuclease activity in
psoriatic scales was at least 3 times greater than
that reported for normal human epidermis by
Santoianni and Rothman (5).
Purification of Psoriatic fiNase. Pooled samples
of psoriatic scales were washed with distilled
water at room temperature and acetone powders
were prepared at 4°. Twenty seven grams of the
acetone powder preparations were extracted with
500 ml of 0.25 N 112S04 for 2 hours at 4° with
shaking. The acid mixture was allowed to stand
in the cold overnight and was then reshaken for
an additional hour. The material was centrifuged
at 4,000 r.p.m. for 30 minutes at 4°. The sediment
was washed with 150 ml of cold 0.25N H2S04.
recentrifuged, and the supernatant solutions
combined (Stage 1). The combined supernatant
solutions were brought to 0.65 ammonium sulfate
saturation (430 g of (NH4)2 504/liter) and the
material stirred in the cold for one hour and then
centrifuged at 4,000 r.p.m. for 30 minutes at 4°.
The supernatant solution was brought to 0.8
ammonium sulfate saturation (105 g of (NH4)2
S04/liter). The turbid solution was stirred at 4°
for one hour and then allowed to stand in the
cold overnight without stirring. The fiocculent
precipitate was recovered by centrifugation at
4,000 r.p.m. for 30 minutes at 4° and the super-
natant solution discarded. The precipitate was
taken up in 10 ml of distilled water and turbidity
was removed by centrifugation at 18,000 r.p.m.
for 30 mm. at 4° (Stage 2). The enzyme solution
was heated at 90° for 3 mm. in a water bath and
TABLE I
Purification of Psoriatic RNase
The assays were carried out as described in the
text.
Treatment Enzyme Tjnits° SpecificActivityt
Stage 1 (112504)
Stage 2 (0.65—0.8 AS.)
Stage 3 (90°)












* One enzyme unit is that amount which will
liberate 0.1 ,zmoles of nucleotide per incubation
mixture. An optical density of 10 at 260 mp was
assumed to be equivalent to 1 mM uranyl acetate-
soluble nucleotide (16).
t Units per mg of protein.
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FIG. 2. Sedimentation characteristics of psoriatic RNase at Stage 4 of purification (cf. Table I) in
0.02M Tris-HC1 buffer of pH 7.2 containing 0.1M NaC1. The protein concentration was 7 mg per ml;
temperature, 4°; speed, 59,780 r.p.m.; bar angle, 60° for pictures (1) and (2) and 50° for pictures (3)—(10). Photographs were taken at 16-minute intervals after reaching maximal speed.
immediately cooled by immersion in an ice
bath. The flocculent precipitate was removed by
centrifugation at 18,000 r.p.m. for 30 mm. at 4°
(Stage 3). The enzyme solution was concentrated
to a volume of 2 ml by ultrafiltration at 4° under
vacuum, using Visking cellulose casing. The
concentrated solution was dialyzed against a
0.02 M Tris-HC1 buffer solution of pH 7.2 over-
night in the cold. The dialyzed material was
centrifuged to remove fiocculent material. The
supernatant solution was brought to 0.8 am-
monium sulfate saturation and allowed to stand
at 4° overnight. The material was then centri-
fuged at 4,000 r.p.m. for 20 mm. at 4°. The sedi-
ment was dissolved in 2 ml of 0.02 M Tris-HCI
buffer of pH 7.2 containing 0.1 M NaC1 and
dialyzed for four hours at 4° against this buffer
solution (Stage 4). The dialyzed enzyme solution
was mixed with 5 volumes of 0.05 M NaHCO3
solution and applied to a DEAE column which
had been equilibrated with a 0.05 M NaHCO1
solution. The enzyme was washed through the
column using a 0.05 M NaHCO3 solution as
eluent (Stage 5). The procedure yielded a RNase
preparation which had been purified approxi-
mately 25-fold (Table I).
Ultracerttriju gal Analysis* of Psoriatic RNase.
The sedimentation characteristics of psoriatic
RNase at Stage 4 of purification were determined
* We wish to thank Dr. Rudy H. Haschemeyer
of the Biochemistry Department, Tufts IJniver-
sity School of Medicine, for making the ultra-
centrifuge runs.
in a Spinco Model E analytical ultracentrifuge.
The enzyme sedimented as a single homogeneous
component with a sedimentation coefficient of
54° = 1.6 X 10 (Fig. 2). Ultracentrifugal
analysis of psoriatic RNase at Stage 4 of purifica-
tion using a double sector cell with the buffer
dialysate as base line also revealed one homogene-
ous component of very low molecular weight.
Starch Gel Electrophoresis. The limitation of
ultracentrifugal analysis in determining homo-
geneity lies in its failure to reveal whether a
single component represents one molecular com-
ponent or several molecular components of the
same molecular weight. For this reason, psoriatic
RNasc at Stage 4 of purification, i.e., before
DEAE treatment, was examined by starch gel
electrophoresis. Psoriatic RNase, although homo-
geneous on ultracentrifugal analysis, was found
to contain several components on electrophoretic
analysis (Fig. 3). It contained two major com-
ponents migrating toward the cathode and
several small components migrating toward the
anode. Of the 2 components migrating toward
the cathode one moved at a rate much faster than
that of pancreatic RNase. This fast moving
component subsequently was identified as psori-
atic RNase.
In view of the heterogeneous nature of the
enzyme preparation at Stage 4 of purification,
further purification was achieved using a 1 x 20
cm DEAE column. The elution pattern of the
protein passing through a DEAE column with a
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0.05 M NaIICO3 solution as eluent showed one
major protein peak extending from tubes 8—11
(Fig. 4). In tube 8 the RNase had a specific
activity of 177; in tube 9, one of 103; in tube 10,
FIG. 3. Starch gel electrophoresis of psoriatic
RNase and crystalline bovine pancreatic RNase
using the discontinuous borate buffer system,
pH 8.0. Sample 3 corresponds to crystalline bo-
vine pancreatic RNase and sample 4 to psoriatic




one of 88; and in tube 11, one of 29. Thus, ilNase
activity was highest in tube S and then decreased
progressively. The proteins eluted in the single
peak extending from tubes S to 11 consisted of
the two protein components which had migrated
toward the cathode on starch gel electrophoresis
(cf. Fig. 3), while the proteins which had mi-
grated toward the anode were retained by the
DEAE column. Psoriatic RNase was eluted
first, followed by a second protein component of
unknown nature which did not possess RNase
activity.
The material in tubes S through 11 obtained
from the DEAE column was concentrated and
resubmitted to starch gel electrophoresis. The
material in tube 5, which contained psoriatic
RNase of the highest specific activity, consisted
of only one component which moved toward the
cathode at a much faster rate than crystalline
bovine pancreatic RNase (Fig. 5). The second
protein component which migrated toward the
cathode at a slower rate than psoriatic RNase
was eluted from the DEAE column after psoriatic
RNase. The ratio of psoriatic RNase to this
second component progressively decreased from
tubes 9 through 11.
Substrate Specificity of Psoriatic RNase. After
Fiu. 4. Elution pattern of psoriatic RNase which had been applied to a 1 X 20 cm DEAE column at













Fin. 5. Starch gel electrophoresis of psoriatic
RNase in tubes 8, 9, 10, and 11 obtained after
DEAE elution, and of crystalline bovine pan-
creatic RNase (p) using a discontinuous buffer
system, pH 8.0.
TABLE II
Purine and Pyrimidine Composition of RNA Before
and After Treatment with Psoriatic RNase
The purine and pyrimidine composition of
purified yeast RNA before and after prolonged
incubation with psoriatic RNase was determined
on HC1O4 hydrolysates of the untreated RNA and
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prolonged incubation of yeast RNA with psoriatic
RNase there was in the resulting "core" RNA
a decrease in the relative concentration of the two
pyrimidines (cytosine and uracil) and an increase
in the relative concentration of the two purines
(adenine and guanine) (Table II). The ratio of
purines to pyrimidines in the yeast RNA before
treatment with psoriatic RNase was approxi-
mately 1 to 1, while after treatment the ratio was
2.8 to 1. This indicates that the substrate specific-
ity of psoriatic RNase is the same as that of
bovine pancreatic RNase, namely, hydrolysis
of the phosphodiester linkages involving the
pyrimidine moieties of the RNA molecule (17).
PH
Fin. 6. pH dependency of psoriatic RNase. pH
5.0, 0.1 M sodium acetate buffer; pH 5.8 and 6.6,
0.1 M sodium phosphate buffer; pH 7.4 and 8.0,
0.1 M Tris-HC1 buffer.
pH Dependency of Psoriatic RNase. The pH
optimum of psoriatic RNase was approximately
6.6 (Fig. 6).
Immunochemistry of Psoriatic RNase. Psoriatic
RNase was found to be immunochemically
distinct from crystalline bovine pancreatic RNase
since, on using the Ouchterlony agar double
diffusion technic (18), it did not cross react with
antibody to pancreatic RNasef (Fig. 7).
DISCUSSION
We have found ribonuclease in psoriatic scales
in high concentration, at least 3 times greater
than that found in normal human epidermis by
Santoianni and Rothman (5). Therefore, RNA
accumulation does not result from a deficiency
of this enzyme. Our finding is in agreement
with the suggestion of Wheatley and Farber; (2)
that the high concentration of RNA in psori-
atic scales is the result of excessive formation
rather than of impaired breakdown. We did not
determine whether or not psoriatic scales con-
tain a physiological RNase inhibitor as Roth
has found in rat liver (19, 20).
Psoriatic RNase has a sedimentation coefficient
of S4 = 1.6 x 10—'. In comparison, bovine
f Pancreatic RNase antibody supplied by Dr.
Mayo Uziel of the Walker Biochemical Labora-
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FIG. 7. Agar double diffusion, using antibody to bovine pancreatic RNase in top center well, crys-
talline bovine pancreatic RNase in bottom right well, and purified psoriatic RNase in bottom left well.
pancreatic RNase has an 2o = 1.88 x 10
(21) and a molecular weight of 13,700 (22). On
the basis of its sedimentation velocity, psoriatic
RNase also can be assumed to have a very low
molecular weight in the order of 14,000. Psoriatic
RNase was also similar to bovine pancreatic
RNase in its reaction specificity since it specifi-
cally hydrolyzed the phosphodiester linkages
involving the pyrimidine moieties of the RNA
molecule. However, electrophoretic analysis
indicated that it was a much more basic protein
than bovine pancreatic RNase and as might be
expected, psoriatic RNase was immunochemically
distinct from bovine pancreatic RNase.
We have shown that in addition to the high
RNA and DNA content reported by Wheatley
and Farber (2), psoriatic scales contain a high
RNase activity. Whereas, both RNA and DNA
are degraded during normal epidermal keratiniza-
tion, they persist in psoriasis. It is noteworthy
that although psoriatic scales contain large
amounts of free uracil (2), we have found the
nucleotide present in lowest concentration in the
RNA of psoriatic scales was uridylic acid (23).
The functions of RNA as a reactant and of DNA
as the specificity determinant in protein bio-
synthesis indicate that the anomalous protein
synthesis in psoriasis probably results from a
disturbed nucleic acid metabolism.
SUMMARY
RNase was found to be present in high con-
centration in psoriatic scales. Therefore, RNA
accumulation does not result from a deficiency
of this enzyme.
The RNase present in psoriatic scales has a very
low molecular weight and is, like pancreatic
RNase, specific for the phosphodiestcr linkages
involving the pyrimidine moieties of RNA. The
enzyme is a more basic protein than pancreatic
RNase.
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DISCUSSION
DR. DAPHNE ANDERSON ROE, Ithaca, N. Y.:
I iery much enjoyed Dr. Liss's paper. I would
like to ask him whether he has had any evidence
that there is high ribonuelease inhibitor activity
in psoniatie epidermis? In actual practice, there
is inhibition of this catabolic process. The fact
that there are maeromoleeular substances in the
psoriatic epidermis suggests a medium for ribonu-
elease inhibition. It is known from previous cx-
periments that maeromoleeular substances can
act as RNase inhibitors. Our own recent studies
have supported this.
DR. MAURICE Liss, (in closing): In answer to
Dr. Roe's question, it is known that there are
RNase inhibitors in other tissues. We have not
determined whether or not any physiological
inhibitors of RNase are present in psoriatie
scales.
